**Application No.: 10/781,442** Attorney Docket No.: 017092-0015-999

Cam No.: 011104-999046

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

lication of:

Wu, et al.

Confirmation No.:

3434

Serial No.:

10/781,442

Art Unit:

1626

Filed:

February 18, 2004

Examiner:

Grazier, Nyeemah

For:

Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9

Attorney Docket No.: 017092-0046-999

**Antagonists** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **DECLARATION OF ROBERT V. MARKET UNDER 37 C.F.R. § 1.132**

Sir:

## I, Robert V. Market declare that:

- 1. I am a co-inventor of the above-identified patent application, and thus am intimately familiar with the subject matter disclosed and claimed in the application.
  - 2. My current position at Encysive Pharmaceuticals, Inc. is Principal Chemist II.
- 3. I have an M.S. (1993) in Chemistry from University of Houston at Clear Lake and a J.D. (2003) from South Texas College of Law. I have published over 9 publications and I am a coinventor on 14 patents/published applications.
  - 4. I have reviewed pending claims 6, 7, 8 and 11-15 in the above-referenced application.
- 5. As described in the specification, compounds of formula II as claimed in claim 6 have activity as CCR9 antagonists as measured in the CCR9 FLIPR/FlexStation assay described in the application. (See, pages 30-31). Table 1 below provides CCR9 binding data (IC<sub>50</sub>) for exemplary compounds within the scope of claim 6.

Application No.: 10/781,442 Attorney Docket No.: 017092-0015-999

Cam No.: 011104-999046



Table 1

Structure	CCR9 Binding IC50 (nM)
O S NH NN	63
OF NH STAN	5012
	1698
	316
O S NH HN	10

Application No.: 10/781,442 Attorney Docket No.: 017092-0015-999

Cam No.: 011104-999046

Structure	CCR9 Binding IC50 (nM)
OF S NH NN	10

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 10/7/07

Robert B. Market

Declarant's Signature